Charles River Laboratories International, Inc.
Location
Massachusetts
Founded
1947-02-28
Website
Risk Signals
1057 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Commercial Physical and Biological Research, Testing Laboratories), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about Charles River Laboratories International, Inc.
Live alerts from global media, monitored by Business Radar
2025-04-15 (biospace.com)
Charles River Laboratories Schedules First-Quarter 2025 Earnings Release and Conference Call -
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) will release first-quarter 2025 financial results on Wednesday, May 7th, before the market opens. A conference call has been scheduled to discuss this information on Wednesday, May 7th, at 9:00 a.m. ET.
Read more
2025-02-27 (koreabiomed.com)
NeoImmuneTech leads Korea's biotech bloodbath as IPO firms shed billions on failed promises < Bio < Article -
The optimism that once fueled Korea's biotech boom has come up against a harsh reality. The promise of rapid profitability that once drove investor excitement has given way to mounting losses, regulatory scrutiny, and a reckoning for firms that set sky-high expectations. Since 2021, 13 biotech firms
Read more
2025-02-19 (tradingview.com)
Charles River Laboratories Reports Q4 and Full-Year 2024 Results — News
Charles River Laboratories International, Inc. has released its financial results for the fourth quarter and full-year 2024, along with its guidance for 2025. The company, which provides essential products and services to pharmaceutical and biotechnology companies, reported a mixed performance with…
Read more
2025-02-19 (stocktitan.net)
Charles River Labs Posts Q4 Loss on $215M Impairment, Forecasts 2025 Revenue Decline | CRL Stock News
CRL reports Q4 revenue of $1B amid biotech spending constraints. Plans $350M stock buyback for 2025 despite projecting 3.5-5.5% organic revenue decline.
Read more
2025-02-19 (nasdaq.com)
CRL Stock Up on Q4 Earnings and Revenue Beat, Margins Fall |
Charles River's organic revenue growth in Manufacturing Solutions is more than offset by lower revenues in the RMS and DSA segments.
Read more
2025-02-06 (marketbeat.com)
E. Ohman J or Asset Management AB Has $480,000 Position in Charles River Laboratories International, Inc. (NYSE:CRL)
E. Ohman J or Asset Management AB grew its position in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 225.0% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,600 shares of th
Read more
2025-01-28 (businesswire.com)
Charles River Laboratories Schedules Fourth-Quarter 2024 Earnings and 2025 Guidance Release and Conference Call | Business Wire
Charles River Laboratories Schedules Fourth-Quarter 2024 Earnings and 2025 Guidance Release and Conference Call
Read more
2025-01-24 (marketbeat.com)
Veracity Capital LLC Acquires New Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)
Veracity Capital LLC purchased a new stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 3,191 shares of the medical research company'
Read more
2025-01-22 (investing.com)
TD Cowen Cuts Charles River Labs Price Target Amid Revenue Pressures By Investing.com
TD Cowen Cuts Charles River Labs Price Target Due to Earnings Pressure
Read more